Literature DB >> 18235120

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.

Anil K Chaturvedi1, Eric A Engels, William F Anderson, Maura L Gillison.   

Abstract

PURPOSE: To investigate the impact of human papillomavirus (HPV) on the epidemiology of oral squamous cell carcinomas (OSCCs) in the United States, we assessed differences in patient characteristics, incidence, and survival between potentially HPV-related and HPV-unrelated OSCC sites. PATIENTS AND METHODS: Data from nine Surveillance, Epidemiology, and End Results program registries (1973 to 2004) were used to classify OSCCs by anatomic site as potentially HPV-related (n = 17,625) or HPV-unrelated (n = 28,144). Joinpoint regression and age-period-cohort models were used to assess incidence trends. Life-table analyses were used to compare 2-year overall survival for HPV-related and HPV-unrelated OSCCs.
RESULTS: HPV-related OSCCs were diagnosed at younger ages than HPV-unrelated OSCCs (mean ages at diagnosis, 61.0 and 63.8 years, respectively; P < .001). Incidence increased significantly for HPV-related OSCC from 1973 to 2004 (annual percentage change [APC] = 0.80; P < .001), particularly among white men and at younger ages. By contrast, incidence for HPV-unrelated OSCC was stable through 1982 (APC = 0.82; P = .186) and declined significantly during 1983 to 2004 (APC = -1.85; P < .001). When treated with radiation, improvements in 2-year survival across calendar periods were more pronounced for HPV-related OSCCs (absolute increase in survival from 1973 through 1982 to 1993 through 2004 for localized, regional, and distant stages = 9.9%, 23.1%, and 18.6%, respectively) than HPV-unrelated OSCCs (5.6%, 3.1%, and 9.9%, respectively). During 1993 to 2004, for all stages treated with radiation, patients with HPV-related OSCCs had significantly higher survival rates than those with HPV-unrelated OSCCs.
CONCLUSION: The proportion of OSCCs that are potentially HPV-related increased in the United States from 1973 to 2004, perhaps as a result of changing sexual behaviors. Recent improvements in survival with radiotherapy may be due in part to a shift in the etiology of OSCCs.

Entities:  

Mesh:

Year:  2008        PMID: 18235120     DOI: 10.1200/JCO.2007.14.1713

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  514 in total

1.  Economic Analysis of a Three-Arm RCT Exploring the Delivery of Intensive, Prophylactic Swallowing Therapy to Patients with Head and Neck Cancer During (Chemo)Radiotherapy.

Authors:  Laurelie R Wall; Sanjeewa Kularatna; Elizabeth C Ward; Bena Cartmill; Anne J Hill; Elizabeth Isenring; Joshua Byrnes; Sandro V Porceddu
Journal:  Dysphagia       Date:  2018-12-04       Impact factor: 3.438

Review 2.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

Review 3.  Racial Disparity Among the Head and Neck Cancer Population.

Authors:  Pedram Daraei; Charles E Moore
Journal:  J Cancer Educ       Date:  2015-09       Impact factor: 2.037

4.  Epidemiology of head and neck squamous cell cancer among HIV-infected patients.

Authors:  Gypsyamber Dʼsouza; Thomas E Carey; William N William; Minh Ly Nguyen; Eric C Ko; James Riddell; Sara I Pai; Vishal Gupta; Heather M Walline; J Jack Lee; Gregory T Wolf; Dong M Shin; Jennifer R Grandis; Robert L Ferris
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-15       Impact factor: 3.731

Review 5.  The role of high-risk human papillomavirus infections in laryngeal squamous cell carcinoma.

Authors:  Claus Wittekindt; Nora Wuerdemann; Stefan Gattenlöhner; Alexander Brobeil; Malgorzata Wierzbicka; Steffen Wagner; Jens Peter Klußmann
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-08-31       Impact factor: 2.503

6.  A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Authors:  Julie E Bauman; Hugo Arias-Pulido; Sang-Joon Lee; M Houman Fekrazad; Hiroyuki Ozawa; Elana Fertig; Jason Howard; Justin Bishop; Hao Wang; Garth T Olson; Michael J Spafford; Dennie V Jones; Christine H Chung
Journal:  Oral Oncol       Date:  2013-02-04       Impact factor: 5.337

7.  Priorities, concerns, and regret among patients with head and neck cancer.

Authors:  Melina J Windon; Gypsyamber D'Souza; Farhoud Faraji; Tanya Troy; Wayne M Koch; Christine G Gourin; Ana P Kiess; Karen T Pitman; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

8.  Reduced feeding tube duration with intensity-modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results-Medicare Analysis.

Authors:  Beth M Beadle; Kai-Ping Liao; Sharon H Giordano; Adam S Garden; Katherine A Hutcheson; Stephen Y Lai; B Ashleigh Guadagnolo
Journal:  Cancer       Date:  2016-09-23       Impact factor: 6.860

9.  Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.

Authors:  Gypsyamber D'Souza; Neil D Gross; Sara I Pai; Robert Haddad; Karen S Anderson; Shirani Rajan; Jennifer Gerber; Maura L Gillison; Marshall R Posner
Journal:  J Clin Oncol       Date:  2014-04-28       Impact factor: 44.544

10.  MMP-7 expression may influence the rate of distant recurrences and disease-specific survival in HPV-positive oropharyngeal squamous cell carcinoma.

Authors:  Seija I Vento; Lauri Jouhi; Hesham Mohamed; Caj Haglund; Antti A Mäkitie; Timo Atula; Jaana Hagström; Laura K Mäkinen
Journal:  Virchows Arch       Date:  2018-05-02       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.